WuXi AppTec

Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks.

China-focused Tigermed staves off biopharma gloom

Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks Key Takeaways: Tigermed…
3347.HK 300347.SHE
WuXi AppTec has recently come under fire from U.S. politicians who want to ban government-backed projects from buying its services, causing the stock to lose about half of its value this year.

FAST NEWS: BlackRock boosts stake in battered WuXi AppTec

The latest: Asset management company BlackRock Inc. purchased 618,000 Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on March 26, raising its stake in the drug outsourcing services company from…
2359.HK 603259.SHG
U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec for HK$75.33 million on Feb. 8.

FAST NEWS: JPMorgan boosts WuXi AppTec stake

The latest: U.S. banking giant JPMorgan purchased 1.57 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$75.33 million ($9.66 million) on Feb. 8, raising its stake in the drug…
2359.HK 603259.SHG
Imminent US targeting casts shadow over future of WuXi AppTec

Potential U.S. targeting casts shadow over WuXi AppTec family

Proposed U.S. legislation could ban federal agencies and federally funded institutions from buying devices and services from Chinese biotech companies Key Takeaways: WuXi AppTec, which could be banned from doing…
2359.HK 603259.SHG
Contract drug services provider WuXi Biologics announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a slowdown in biotech financing, after seeing a strong recovery in demand in the second half of last year.

FAST NEWS: WuXi Biologics boosts new projects target

The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…
2269.HK

Recent Articles

RELATED ARTICLES

  1. WuXi Biologics is spinning off its WuXi XDC ADS unit
    WuXi Biologics hatches new baby with ADC drug unit IPO
    2269.HK
  2. Potential U.S. targeting casts shadow over WuXi AppTec family
    2359.HK 603259.SHG
  3. WuXi Bio prescribes share buyback to relieve revenue pain
    2269.HK
  4. FAST NEWS: JPMorgan boosts WuXi AppTec stake
    2359.HK 603259.SHG
  5. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  6. InSilico seeks IPO boost to get AI drugs over the line
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva